ALB and chronic kidney disease: Additionally, tolvaptan has been shown to decrease the incidence of AKI in patients with acute decompensated heart failure and advanced chronic kidney disease (35).The association between the administration of human blood albumin and the incidence of acute kidney injury is a topic of debate (36, 37).